Literature DB >> 26690810

Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?

Kenneth I Berns1,2,3, Barry J Byrne1,2,3,4, Terence R Flotte5,6, Guangping Gao6,7, William W Hauswirth2,8, Roland W Herzog1,2,3,4, Nicholas Muzyczka1,2,3, Thierry VandenDriessche9, Xiao Xiao10,11, Sergei Zolotukhin1,2,3,4, Arun Srivastava1,2,3,4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26690810      PMCID： PMC4809064          DOI： 10.1089/hum.2015.29014.kib

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  20 in total

1.  Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors.

Authors:  Shaoyong Li; Chen Ling; Li Zhong; Mengxin Li; Qin Su; Ran He; Qiushi Tang; Dale L Greiner; Leonard D Shultz; Michael A Brehm; Terence R Flotte; Christian Mueller; Arun Srivastava; Guangping Gao
Journal:  Mol Ther       Date:  2015-09-25       Impact factor: 11.454

2.  Inhibition of H-ras expression by the adeno-associated virus Rep78 transformation suppressor gene product.

Authors:  P L Hermonat
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

3.  Influence of adeno-associated satellite virus on adenovirus-induced tumours in hamsters.

Authors:  H D Mayor; G S Houlditch; D M Mumford
Journal:  Nat New Biol       Date:  1973-01-10

4.  Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus.

Authors:  J M Ostrove; D H Duckworth; K I Berns
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

5.  Effect of adeno-associated virus on cancer expression by herpesvirus-transformed hamster cells.

Authors:  G Cukor; N R Blacklow; S Kibrick; I C Swan
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

6.  Virus-mediated killing of cells that lack p53 activity.

Authors:  K Raj; P Ogston; P Beard
Journal:  Nature       Date:  2001-08-30       Impact factor: 49.962

7.  A seroepidemiologic study of adenovirus-associated virus infection in infants and children.

Authors:  N R Blacklow; M D Hoggan; M S Sereno; C D Brandt; H W Kim; R H Parrott; R M Chanock
Journal:  Am J Epidemiol       Date:  1971-10       Impact factor: 4.897

8.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.

Authors:  Jean-Charles Nault; Shalini Datta; Sandrine Imbeaud; Andrea Franconi; Maxime Mallet; Gabrielle Couchy; Eric Letouzé; Camilla Pilati; Benjamin Verret; Jean-Frédéric Blanc; Charles Balabaud; Julien Calderaro; Alexis Laurent; Mélanie Letexier; Paulette Bioulac-Sage; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-08-24       Impact factor: 38.330

9.  Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults.

Authors:  H D Mayor; S Drake; J Stahmann; D M Mumford
Journal:  Am J Obstet Gynecol       Date:  1976-09-01       Impact factor: 8.661

10.  Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus.

Authors:  B Georg-Fries; S Biederlack; J Wolf; H zur Hausen
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616
View more
  32 in total

Review 1.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

2.  Reply to "Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV".

Authors:  Manfred Schmidt; Irene Gil-Farina; Hildegard Büning
Journal:  Mol Ther       Date:  2016-04       Impact factor: 11.454

3.  Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for Human Gene Therapy?

Authors:  Randy J Chandler; Matthew C LaFave; Gaurav K Varshney; Shawn M Burgess; Charles P Venditti
Journal:  Mol Ther       Date:  2016-02       Impact factor: 11.454

4.  Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.

Authors:  Grant J Logan; Allison P Dane; Claus V Hallwirth; Christine M Smyth; Emilie E Wilkie; Anais K Amaya; Erhua Zhu; Neeta Khandekar; Samantha L Ginn; Sophia H Y Liao; Sharon C Cunningham; Natsuki Sasaki; Martí Cabanes-Creus; Patrick P L Tam; David W Russell; Leszek Lisowski; Ian E Alexander
Journal:  Nat Genet       Date:  2017-06-19       Impact factor: 38.330

5.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

6.  Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections.

Authors:  Jeffrey D Rubin; Tien V Nguyen; Kari L Allen; Katayoun Ayasoufi; Michael A Barry
Journal:  Hum Gene Ther       Date:  2019-12-03       Impact factor: 5.695

7.  AAV Infection: Protection from Cancer.

Authors:  Arun Srivastava; Barrie J Carter
Journal:  Hum Gene Ther       Date:  2016-11-10       Impact factor: 5.695

8.  Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque.

Authors:  K Tyler McCullough; Sanford L Boye; Diego Fajardo; Kaitlyn Calabro; James J Peterson; Christianne E Strang; Dibyendu Chakraborty; Sebastian Gloskowski; Scott Haskett; Steven Samuelsson; Haiyan Jiang; C Douglas Witherspoon; Paul D Gamlin; Morgan L Maeder; Shannon E Boye
Journal:  Hum Gene Ther       Date:  2018-12-20       Impact factor: 5.695

9.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

Review 10.  Cell and gene therapy strategies to eradicate HIV reservoirs.

Authors:  Chelsea Spragg; Harshana De Silva Feelixge; Keith R Jerome
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.